PubRank

Peter A Andreasen

Author PubWeight™ 48.11‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion. Am J Pathol 2009 1.15
2 Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost 2004 1.11
3 The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol 2003 1.05
4 Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C. J Biol Chem 2006 1.04
5 Cantilever sensor for nanomechanical detection of specific protein conformations. Nano Lett 2005 1.02
6 Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis. FEBS J 2006 0.97
7 The vitronectin binding area of plasminogen activator inhibitor-1, mapped by mutagenesis and protection against an inactivating organochemical ligand. FEBS Lett 2002 0.96
8 Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1. J Biol Chem 2011 0.96
9 Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells. Neoplasia 2011 0.93
10 The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment. Biol Chem 2002 0.92
11 Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1. Biochem J 2003 0.91
12 A novel mode of intervention with serine protease activity: targeting zymogen activation. J Biol Chem 2008 0.91
13 Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1. Am J Clin Pathol 2004 0.90
14 RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1. Biochemistry 2010 0.90
15 Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain. J Biol Chem 2008 0.89
16 The mosaic receptor sorLA/LR11 binds components of the plasminogen-activating system and platelet-derived growth factor-BB similarly to LRP1 (low-density lipoprotein receptor-related protein), but mediates slow internalization of bound ligand. Biochem J 2004 0.88
17 Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1. J Struct Biol 2007 0.88
18 Vitronectin in human breast carcinomas. Biochim Biophys Acta 2003 0.87
19 Mutational analysis of plasminogen activator inhibitor-1. Eur J Biochem 2003 0.87
20 Structural insight into inactivation of plasminogen activator inhibitor-1 by a small-molecule antagonist. Chem Biol 2013 0.87
21 A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition. J Biol Chem 2005 0.87
22 Construction of a plasminogen activator inhibitor-1 variant without measurable affinity to vitronectin but otherwise normal. FEBS Lett 2004 0.87
23 Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases. J Biol Chem 2004 0.87
24 Plasminogen activator inhibitor-1 is an inhibitor of factor VII-activating protease in patients with acute respiratory distress syndrome. J Biol Chem 2007 0.86
25 Hydrogen/deuterium exchange mass spectrometry reveals specific changes in the local flexibility of plasminogen activator inhibitor 1 upon binding to the somatomedin B domain of vitronectin. Biochemistry 2012 0.86
26 Dissecting the effect of RNA aptamer binding on the dynamics of plasminogen activator inhibitor 1 using hydrogen/deuterium exchange mass spectrometry. ACS Chem Biol 2013 0.86
27 Biochemical importance of glycosylation of plasminogen activator inhibitor-1. Thromb Haemost 2003 0.86
28 The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation. Biochem J 2003 0.86
29 Local transient unfolding of native state PAI-1 associated with serpin metastability. Angew Chem Int Ed Engl 2014 0.86
30 Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands. Biochem J 2003 0.85
31 Overexpression of protease nexin-1 mRNA and protein in oral squamous cell carcinomas. Oral Oncol 2007 0.85
32 Epigenetic alterations of the SERPINE1 gene in oral squamous cell carcinomas and normal oral mucosa. Genes Chromosomes Cancer 2010 0.85
33 CpG methylation of the PAI-1 gene 5'-flanking region is inversely correlated with PAI-1 mRNA levels in human cell lines. Thromb Haemost 2005 0.85
34 Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability. J Biol Chem 2011 0.84
35 A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state. Mol Pharmacol 2008 0.84
36 Redirection of the reaction between activated protein C and a serpin to the substrate pathway. Thromb Res 2007 0.83
37 Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility. J Mol Biol 2011 0.83
38 A novel pesticide-induced conformational state of the oestrogen receptor ligand-binding domain, detected by conformation-specific peptide binding. FEBS Lett 2005 0.83
39 Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs. Mol Pharmacol 2011 0.83
40 Mapping of the epitope of a monoclonal antibody protecting plasminogen activator inhibitor-1 against inactivating agents. Eur J Biochem 2003 0.82
41 Protein conformational change delayed by steric hindrance from an N-linked glycan. J Mol Biol 2013 0.81
42 Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements. Biochemistry 2009 0.80
43 A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue. Biochem J 2008 0.79
44 Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies. Biochem J 2011 0.79
45 Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism. Mol Cancer Res 2012 0.79
46 Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library. Biochem J 2006 0.79
47 The role of beta-strand 5A of plasminogen activator inhibitor-1 in regulation of its latency transition and inhibitory activity by vitronectin. Biochim Biophys Acta 2002 0.78
48 Bicyclic peptide inhibitor of urokinase-type plasminogen activator: mode of action. Chembiochem 2013 0.78
49 The binding mechanism of a peptidic cyclic serine protease inhibitor. J Mol Biol 2011 0.78
50 Nonproteolytic induction of catalytic activity into the single-chain form of urokinase-type plasminogen activator by dipeptides. Biochemistry 2009 0.77
51 Antibody-induced enhancement of factor VIIa activity through distinct allosteric pathways. J Biol Chem 2012 0.77
52 Allosteric inactivation of a trypsin-like serine protease by an antibody binding to the 37- and 70-loops. Biochemistry 2013 0.77
53 Novel modes of oestrogen receptor agonism and antagonism by hydroxylated and chlorinated biphenyls, revealed by conformation-specific peptide recognition patterns. Mol Cell Endocrinol 2008 0.76
54 Three monoclonal antibodies against the serpin protease nexin-1 prevent protease translocation. Thromb Haemost 2013 0.76
55 Rezymogenation of active urokinase induced by an inhibitory antibody. Biochem J 2013 0.76
56 Urokinase-type plasminogen activator-like proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains. J Biol Chem 2012 0.75
57 DNA Methylation Profiles of Protease Nexin 1 (SERPINE2) Gene in Human Cell Lines. Chin J Cancer Res 2011 0.75
58 Latency transition of plasminogen activator inhibitor type 1 is evolutionarily conserved. Thromb Haemost 2017 0.75
59 Interconversion of active and inactive conformations of urokinase-type plasminogen activator. Biochemistry 2012 0.75
60 Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation. Thromb Haemost 2015 0.75